Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs

Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs

来源:Barrons发布于 2026-11-16

Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.

相关标的:AZNSMMT

本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。